Celcuity (NASDAQ:CELC) Sets New 1-Year High – Should You Buy?

Celcuity, Inc. (NASDAQ:CELC) reached a new 52-week high on Thursday . The stock traded as high as $104.81 and last traded at $104.4960, with a volume of 189091 shares traded. The stock had previously closed at $100.00.

Analyst Upgrades and Downgrades

Several analysts have commented on the company. Craig Hallum lifted their price target on Celcuity from $96.00 to $108.00 and gave the company a “buy” rating in a report on Thursday, November 13th. Wall Street Zen lowered shares of Celcuity from a “hold” rating to a “sell” rating in a report on Sunday, October 26th. HC Wainwright reaffirmed a “neutral” rating and issued a $94.00 target price (up from $77.00) on shares of Celcuity in a research report on Monday, November 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Celcuity in a research report on Wednesday, October 8th. Finally, Guggenheim started coverage on Celcuity in a report on Monday, September 22nd. They issued a “buy” rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Celcuity currently has an average rating of “Moderate Buy” and an average price target of $102.29.

Celcuity Stock Up 5.3%

The stock has a market capitalization of $4.87 billion, a price-to-earnings ratio of -28.69 and a beta of 0.21. The firm has a 50-day moving average of $72.56 and a 200 day moving average of $44.84. The company has a current ratio of 12.26, a quick ratio of 12.26 and a debt-to-equity ratio of 2.74.

Celcuity (NASDAQ:CELC) last posted its earnings results on Wednesday, November 12th. The company reported ($0.92) EPS for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.13. On average, sell-side analysts anticipate that Celcuity, Inc. will post -2.62 earnings per share for the current year.

Insider Buying and Selling at Celcuity

In other news, Director Richard E. Buller sold 3,900 shares of Celcuity stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $96.73, for a total transaction of $377,247.00. Following the sale, the director directly owned 7,260 shares of the company’s stock, valued at approximately $702,259.80. The trade was a 34.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 15.77% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Celcuity

A number of hedge funds have recently bought and sold shares of the business. Gagnon Securities LLC raised its position in shares of Celcuity by 3.5% in the 1st quarter. Gagnon Securities LLC now owns 54,310 shares of the company’s stock valued at $549,000 after purchasing an additional 1,831 shares in the last quarter. Nuveen LLC bought a new stake in shares of Celcuity in the first quarter worth $704,000. Wellington Management Group LLP boosted its stake in Celcuity by 35.1% during the 1st quarter. Wellington Management Group LLP now owns 84,825 shares of the company’s stock valued at $858,000 after acquiring an additional 22,049 shares during the last quarter. EntryPoint Capital LLC grew its holdings in Celcuity by 18.4% during the 1st quarter. EntryPoint Capital LLC now owns 24,687 shares of the company’s stock worth $250,000 after acquiring an additional 3,840 shares in the last quarter. Finally, Trexquant Investment LP increased its position in shares of Celcuity by 131.3% in the 1st quarter. Trexquant Investment LP now owns 26,920 shares of the company’s stock worth $272,000 after purchasing an additional 15,280 shares during the last quarter. Institutional investors and hedge funds own 63.33% of the company’s stock.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.